

Author Index Volume 33 (2012)

The issue number is given in front of the pagination

- Abolhalaj, M., see Khojasteh-Fard, M. (6) 289–293
Al Robae, A.A., see Al-Shobaili, H.A. (1) 19–34
Albayrak, M., see Belen, F.B. (1) 11–18
Al-Shobaili, H.A., A.A. Al Robae, A.A. Alzolibani and Z. Rasheed, Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: Role of chromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE (1) 19–34
Alzolibani, A.A., see Al-Shobaili, H.A. (1) 19–34
Amiri, P., see Khojasteh-Fard, M. (6) 289–293
Amoli, M.M., see Khojasteh-Fard, M. (6) 289–293
Anichini, C., F. Lotti, M. Longini, F. Proietti, C. Felici, S. Perrone and G. Buonocore, Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome (4) 179–183
Anjana, R.M., see Indulekha, K. (4) 185–192
Aravindhan, V., see Indulekha, K. (4) 185–192
Areias, A., see Rocha, G. (1) 51–60
Arolt, V., see Morris, C.P. (4) 163–170

Balasubramanyam, M., see Indulekha, K. (4) 185–192
Balatgi, S., see Ferchichi, I. (6) 333–340
Balwierz, W., see Sulicka, J. (2) 69–76
Basu, K., A. Sen, K. Ray, I. Ghosh, K. Datta and A. Mukhopadhyay, Genetic association and gene-gene interaction of *HAS2*, *HABP1* and *HYAL3* implicate hyaluronan metabolic genes in glaucomatous neurodegeneration (3) 145–154
Baune, B.T., see Morris, C.P. (4) 163–170
Bazzaz, J.T., see Khojasteh-Fard, M. (6) 289–293
Belen, F.B., U. Kocak, M. Albayrak, Z. Kaya and T. Gursel, Diagnostic value of neopterin during neutropenic fever and determination of disease activity in childhood leukemias (1) 11–18
Ben Romdhne, K., see Ferchichi, I. (6) 333–340
Benammar Elgaaied, A., see Ferchichi, I. (6) 333–340
Bienertová-Vašků, J., see Vašků, A. (1) 43–49

Biswas, A., see Sadhukhan, T. (3) 127–135
Blahák, J., see Vašků, A. (1) 43–49
Bokhari, S.N.H., see Shakoori, T.A. (2) 91–100
Bowers, J.M. and G. Konopka, The role of the FOXP family of transcription factors in ASD (5) 251–260
Božić, V., see Janković, J. (6) 321–331
Bozkurt, N., see Yigit, S. (3) 113–118
Bozzi, Y., see Provenzano, G. (5) 225–239
Buonocore, G., see Anichini, C. (4) 179–183

Calkan, M., see Yasar, A. (2) 85–89
Carninci, P., see Saxena, A. (5) 261–275
Carvalho, C., see Rocha, G. (1) 51–60
Chang, J.-P., see Chen, C.-J. (3) 119–126
Chassanidis, C., see Samara, S. (4) 215–221
Chen, C.-J., W.-H. Liu, J.-P. Chang, W.-C. Ho, Y.-L. Chen, C.-Y. Fang and M.-C. Chen, Plasma Creative protein is not related to sinus non-conversion by maze procedure adjunct to mitral valve surgery (3) 119–126
Chen, J., P.K.-T. Li, B.C.-H. Kwan, K.-M. Chow, K.-B. Lai, C.C.-W. Luk and C.-C. Szeto, Relation between microRNA expression in peritoneal dialysis effluent and peritoneal transport characteristics (1) 35–42
Chen, M.-C., see Chen, C.-J. (3) 119–126
Chen, Y.-L., see Chen, C.-J. (3) 119–126
Choi, P.C.-L., see Szeto, C.-C. (3) 137–144
Chow, K.-M., see Chen, J. (1) 35–42
Chow, K.-M., see Szeto, C.-C. (3) 137–144
Clark, D. and L. Mao, Cancer biomarker discovery: Lectin-based strategies targeting glycoproteins (1) 1–10
Colak, Y., E. Senates, E. Coskunpinar, Y.M. Oltulu, E. Zemheri, O. Ozturk, L. Doganay, B. Mesci, Y. Yilmaz, F.Y. Enc, S. Kiziltas, C. Ulasoglu and I. Tuncer, Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis (2) 77–83

- Cooper, J., see Mackness, B. (2) 101–112
 Coskunpinar, E., see Colak, Y. (2) 77–83
 Cremet, J.Y., see Ferchichi, I. (6) 333–340
 Cvejić, D., see Janković, J. (6) 321–331
 Ćwiklińska, M., see Sulicka, J. (2) 69–76
- Dailiana, Z., see Samara, S. (4) 215–221
 Daneri-Navarro, A., see Ramírez-De los Santos, S. (4) 201–206
 Das, S.K., see Sadhukhan, T. (3) 127–135
 Datta, K., see Basu, K. (3) 145–154
 de Castro Ribeiro, M., see Zavalhia, L.S. (2) 61–68
 de Lourdes V Rodrigues, M., see Demarco, A.L.G. (6) 309–312
 de Menezes, M.B., see Demarco, A.L.G. (6) 309–312
 Deghaide, N.H.S., see Demarco, A.L.G. (6) 309–312
 Demarco, A.L.G., M. de Lourdes V Rodrigues, J.F.C. Figueiredo, N.H.S. Deghaide, M.B. de Menezes, L.A. Demarco, A.P.M. Fernandes and E.A. Donadi, Susceptibility to toxoplasmic retinochoroiditis is associated with HLA alleles reported to be implicated with rapid progression to AIDS (6) 309–312
 Demarco, L.A., see Demarco, A.L.G. (6) 309–312
 Derchain, S.F.M., see Oliveira, C. (3) 155–159
 Doganay, L., see Colak, Y. (2) 77–83
 Domschke, K., see Morris, C.P. (4) 163–170
 Donadi, E.A., see Demarco, A.L.G. (6) 309–312
 Dong, Y., see Huang, H. (6) 295–302
 dos Santos, G.T., see Zavalhia, L.S. (2) 61–68
- Elkeles, R.S., see Mackness, B. (2) 101–112
 Enc, F.Y., see Colak, Y. (2) 77–83
- Fang, C.-Y., see Chen, C.-J. (3) 119–126
 Feher, M.D., see Mackness, B. (2) 101–112
 Felici, C., see Anichini, C. (4) 179–183
 Ferchichi, I., N. Kourda, S. Sassi, K. Ben Romdhne, S. Balatgi, J.Y. Cremet, C. Prigent and A. Benammar Elgaaied, Aurora A overexpression and pVHL reduced expression are correlated with a bad kidney cancer prognosis (6) 333–340
 Fernandes, A.P.M., see Demarco, A.L.G. (6) 309–312
 Figueiredo, J.F.C., see Demarco, A.L.G. (6) 309–312
 Flather, M.D., see Mackness, B. (2) 101–112
- García-Iglesias, T., see Ramírez-De los Santos, S. (4) 201–206
 Genovesi, S., see Provenzano, G. (5) 225–239
 Ghafoor, F., see Shakoori, T.A. (2) 91–100
 Ghalaut, V.S., see Kumawat, M. (6) 303–308
- Ghosh, I., see Basu, K. (3) 145–154
 Godsland, I.F., see Mackness, B. (2) 101–112
 Gokulakrishnan, K., see Indulekha, K. (4) 185–192
 Goldbergová, M.P., see Vašků, A. (1) 43–49
 Grodzicki, T.K., see Sulicka, J. (2) 69–76
 Gryglewska, B., see Sulicka, J. (2) 69–76
 Guedes, A., see Rocha, G. (1) 51–60
 Guimaraes, H., see Rocha, G. (1) 51–60
 Gunduz, K., see Yasar, A. (2) 85–89
 Gursel, T., see Belen, F.B. (1) 11–18
 Guzmán-Guzmán, I.P., see Muñoz-Barrios, S. (6) 313–320
- Hilbig, A., see Zavalhia, L.S. (2) 61–68
 Ho, W.-C., see Chen, C.-J. (3) 119–126
 Hong, J.H., H.W. Jang, Y.E. Kang, J.H. Lee, K.S. Kim, H.J. Kim, K.R. Park and B.J. Ku, Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus (4) 193–199
 Hu, V.W., Subphenotype-dependent disease markers for diagnosis and personalized treatment of autism spectrum disorders (5) 277–288
 Huang, H., R. Ma, D. Liu, C. Liu, Y. Ma, W. Mai and Y. Dong, Oxidized low-density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease (6) 295–302
 Hughes, I.P., see Morris, C.P. (4) 163–170
 Humphries, S.E., see Mackness, B. (2) 101–112
- Inanir, A., see Yigit, S. (3) 113–118
 Indulekha, K., J. Surendar, R.M. Anjana, K. Gokulakrishnan, M. Balasubramanyam, V. Aravindhan and V. Mohan, Circulating levels of high molecular weight (HMW) adiponectin and total adiponectin in relation to fat distribution, oxidative stress and inflammation in Asian Indians (4) 185–192
- Jang, H.W., see Hong, J.H. (4) 193–199
 Janković, J., S. Paskaš, I. Marečko, V. Božić, D. Cvejić and S. Savin, Caveolin-1 expression in thyroid neoplasia spectrum: Comparison of two commercial antibodies (6) 321–331
- Kalra, N., see Pradeep, A.R. (4) 207–213
 Kang, Y.E., see Hong, J.H. (4) 193–199
 Karakus, N., see Yigit, S. (3) 113–118
 Kaya, Z., see Belen, F.B. (1) 11–18
 Kesici, E., see Yigit, S. (3) 113–118
 Khojasteh-Fard, M., M. Abolhalaj, P. Amiri, M. Zaki, Z. Taheri, M. Qorbani, J.T. Bazzaz and M.M. Amoli, IL-23 gene expression in PBMCs of patients with coronary artery disease (6) 289–293

- Kim, H.J., see Hong, J.H. (4) 193–199
 Kim, K.S., see Hong, J.H. (4) 193–199
 Kincl, V., see Vašků, A. (1) 43–49
 Kiziltas, S., see Colak, Y. (2) 77–83
 Kocak, U., see Belen, F.B. (1) 11–18
 Kollia, P., see Samara, S. (4) 215–221
 Konopka, G., see Bowers, J.M. (5) 251–260
 Koromila, T., see Samara, S. (4) 215–221
 Kourda, N., see Ferchichi, I. (6) 333–340
 Ku, B.J., see Hong, J.H. (4) 193–199
 Kumari, M., see Pradeep, A.R. (4) 207–213
 Kumawat, M., T.K. Sharma, I. Singh, N. Singh, S.K.
 Singh, V.S. Ghalaut, V. Shankar and S.K. Vardey,
 Decrease in antioxidant status of plasma and ery-
 throcytes from geriatric population (6) 303–308
 Kwan, B.C.-H., see Chen, J. (1) 35–42
 Kwan, B.C.-H., see Szeto, C.-C. (3) 137–144
 Kwater, A., see Sulicka, J. (2) 69–76
- Lai, K.-B., see Chen, J. (1) 35–42
 Lai, K.-B., see Szeto, C.-C. (3) 137–144
 Lawford, B.R., see Morris, C.P. (4) 163–170
 Lee, J.H., see Hong, J.H. (4) 193–199
 Li, P.K.-T., see Chen, J. (1) 35–42
 Li, P.K.-T., see Szeto, C.-C. (3) 137–144
 Lima, C.S.P., see Oliveira, C. (3) 155–159
 Liu, C., see Huang, H. (6) 295–302
 Liu, D., see Huang, H. (6) 295–302
 Liu, W.-H., see Chen, C.-J. (3) 119–126
 Longini, M., see Anichini, C. (4) 179–183
 Lotti, F., see Anichini, C. (4) 179–183
 Lourenço, G.J., see Oliveira, C. (3) 155–159
 Luk, C.C.-W., see Chen, J. (1) 35–42
- Ma, R., see Huang, H. (6) 295–302
 Ma, Y., see Huang, H. (6) 295–302
 Mackness, B., J. Marsillac, R.S. Elkeles, I.F. God-
 sland, M.D. Feher, M.B. Rubens, M.D. Flather,
 S.E. Humphries, J. Cooper and M. Mackness,
 Paraoxonase-1 is not associated with coronary
 artery calcification in type 2 diabetes: Results
 from the PREDICT study (2) 101–112
 Mackness, M., see Mackness, B. (2) 101–112
 Mai, W., see Huang, H. (6) 295–302
 Malizos, K.N., see Samara, S. (4) 215–221
 Mao, L., see Clark, D. (1) 1–10
 Marečko, I., see Janković, J. (6) 321–331
 Marsillac, J., see Mackness, B. (2) 101–112
 Meluzín, J., see Vašků, A. (1) 43–49
 Mesci, B., see Colak, Y. (2) 77–83
 Meurer, R.T., see Zavalhia, L.S. (2) 61–68
- Michałowski, M.B., see Zavalhia, L.S. (2) 61–68
 Mohan, V., see Indulekha, K. (4) 185–192
 Morris, C.P., B.T. Baune, K. Domschke, V. Arolt, C.D.
 Swagell, I.P. Hughes, B.R. Lawford, R.M. Young
 and J. Voisey, *KPNA3* variation is associated with
 schizophrenia, major depression, opiate depen-
 dence and alcohol dependence (4) 163–170
 Mukhopadhyay, A., see Basu, K. (3) 145–154
 Muñoz-Barrios, S., I.P. Guzmán-Guzmán, J.F. Muñz-
 Valle, A.B. Salgado-Bernabé, L. Salgado-Goytia
 and I. Parra-Rojas, Association of the *HindIII* and
 S447X polymorphisms in *LPL* gene with hyper-
 tension and type 2 diabetes in Mexican families
 (6) 313–320
 Muñoz-Valle, J.F., see Ramírez-De los Santos, S. (4)
 201–206
 Muñz-Valle, J.F., see Muñoz-Barrios, S. (6) 313–320
- Netto, G.C., see Zavalhia, L.S. (2) 61–68
- Oliveira, C., G.J. Lourenço, R.A.M. Sagarra, S.F.M.
 Derchain, J.G. Segalla and C.S.P. Lima, Poly-
 morphisms of glutathione S-transferase Mu 1
 (*GSTM1*), Theta 1 (*GSTT1*), and Pi 1 (*GSTP1*)
 genes and epithelial ovarian cancer risk (3) 155–
 159
 Oltulu, Y.M., see Colak, Y. (2) 77–83
 Onur, E., see Yasar, A. (2) 85–89
 Ozturk, O., see Colak, Y. (2) 77–83
- Palafox-Sánchez, C.A., see Ramírez-De los Santos, S.
 (4) 201–206
 Panaitof, S.C., A songbird animal model for dissecting
 the genetic bases of autism spectrum disorder (5)
 241–249
 Papatheodorou, L., see Samara, S. (4) 215–221
 Park, K.R., see Hong, J.H. (4) 193–199
 Parra-Rojas, I., see Muñoz-Barrios, S. (6) 313–320
 Paskaš, S., see Janković, J. (6) 321–331
 Perrone, S., see Anichini, C. (4) 179–183
 Pradeep, A.R., N. Priyanka, M.V.R. Prasad, N. Kalra
 and M. Kumari, Association of progranulin and
 high sensitivity CRP concentrations in gingival
 crevicular fluid and serum in chronic periodontitis
 subjects with and without obesity (4) 207–213
 Prasad, M.V.R., see Pradeep, A.R. (4) 207–213
 Prigent, C., see Ferchichi, I. (6) 333–340
 Priyanka, N., see Pradeep, A.R. (4) 207–213
 Proença, E., see Rocha, G. (1) 51–60
 Proietti, F., see Anichini, C. (4) 179–183

- Provenzano, G., G. Zunino, S. Genovesi, P. Sgadò and Y. Bozzi, Mutant mouse models of autism spectrum disorders (5) 225–239
- Qorbani, M., see Khojasteh-Fard, M. (6) 289–293
- Ramírez-De los Santos, S., P.E. Sánchez-Hernández, J.F. Muñoz-Valle, C.A. Palafox-Sánchez, L.Y. Rosales-Rivera, T. García-Iglesias, A. Danerí-Navarro and M.G. Ramírez-Dueñas, Associations of killer cell immunoglobulin-like receptor genes with rheumatoid arthritis (4) 201–206
- Ramírez-Dueñas, M.G., see Ramírez-De los Santos, S. (4) 201–206
- Ramos, J.P., see Rocha, G. (1) 51–60
- Rasheed, Z., see Al-Shobaili, H.A. (1) 19–34
- Ray, J., see Sadhukhan, T. (3) 127–135
- Ray, K., see Basu, K. (3) 145–154
- Ray, K., see Sadhukhan, T. (3) 127–135
- Rocha, G., E. Proença, A. Guedes, C. Carvalho, A. Areias, J.P. Ramos, T. Rodrigues and H. Guimarães, Cord blood levels of IL-6, IL-8 and IL-10 may be early predictors of bronchopulmonary dysplasia in preterm newborns small for gestational age (1) 51–60
- Rodrigues, T., see Rocha, G. (1) 51–60
- Romitti, M., see Zavalhia, L.S. (2) 61–68
- Rosales-Rivera, L.Y., see Ramírez-De los Santos, S. (4) 201–206
- Rubens, M.B., see Mackness, B. (2) 101–112
- Sadhukhan, T., A. Biswas, S.K. Das, K. Ray and J. Ray, *DJ-1* variants in Indian Parkinson's disease patients (3) 127–135
- Sagarra, R.A.M., see Oliveira, C. (3) 155–159
- Salgado-Bemabé, A.B., see Muñoz-Barrios, S. (6) 313–320
- Salgado-Goytia, L., see Muñoz-Barrios, S. (6) 313–320
- Samara, S., P. Kollia, Z. Dailiana, C. Chassanidis, L. Papatheodorou, T. Koromila and K.N. Malizos, Predictive role of cytokine gene polymorphisms for the development of femoral head osteonecrosis (4) 215–221
- Sánchez-Hernández, P.E., see Ramírez-De los Santos, S. (4) 201–206
- Sassi, S., see Ferchichi, I. (6) 333–340
- Savin, S., see Janković, J. (6) 321–331
- Saxena, A., D. Tang and P. Carninci, piRNAs warrant investigation in Rett Syndrome: An omics perspective (5) 261–275
- Segalla, J.G., see Oliveira, C. (3) 155–159
- Sen, A., see Basu, K. (3) 145–154
- Senates, E., see Colak, Y. (2) 77–83
- Sgadò, P., see Provenzano, G. (5) 225–239
- Shakoori, A.R., see Shakoori, T.A. (2) 91–100
- Shakoori, T.A., D.D. Sin, S.N.H. Bokhari, F. Ghafoor and A.R. Shakoori, SP-D polymorphisms and the risk of COPD (2) 91–100
- Shankar, V., see Kumawat, M. (6) 303–308
- Sharma, T.K., see Kumawat, M. (6) 303–308
- Sin, D.D., see Shakoori, T.A. (2) 91–100
- Singh, I., see Kumawat, M. (6) 303–308
- Singh, N., see Kumawat, M. (6) 303–308
- Singh, S.K., see Kumawat, M. (6) 303–308
- Sitar, J., see Vašků, A. (1) 43–49
- Strach, M., see Sulicka, J. (2) 69–76
- Sulicka, J., A. Surdacki, M. Strach, A. Kwater, B. Gryglewska, M. Ćwiklińska, W. Balwierz and T.K. Grodzicki, Elevated asymmetric dimethylarginine in young adult survivors of childhood acute lymphoblastic leukemia: A preliminary report (2) 69–76
- Sun, X.-F., see Zhu, Z.-L. (4) 171–178
- Surdacki, A., see Sulicka, J. (2) 69–76
- Surendar, J., see Indulekha, K. (4) 185–192
- Swagell, C.D., see Morris, C.P. (4) 163–170
- Szeto, C.-C., B.C.-H. Kwan, K.-B. Lai, P.C.-L. Choi, G. Wang, K.-M. Chow and P.K.-T. Li, Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases (3) 137–144
- Szeto, C.-C., see Chen, J. (1) 35–42
- Taheri, Z., see Khojasteh-Fard, M. (6) 289–293
- Tang, D., see Saxena, A. (5) 261–275
- Tuncer, I., see Colak, Y. (2) 77–83
- Ulasoglu, C., see Colak, Y. (2) 77–83
- Vardey, S.K., see Kumawat, M. (6) 303–308
- Vašků, A., J. Meluzín, J. Blahák, V. Kincl, M.P. Goldbergová, J. Sitar, F. Zlámal, J. Bienertová-Vašků and J. Vítověc, Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease (1) 43–49
- Vítověc, J., see Vašků, A. (1) 43–49
- Voisey, J., see Morris, C.P. (4) 163–170
- Wang, G., see Szeto, C.-C. (3) 137–144
- Wang, M.-W., see Zhu, Z.-L. (4) 171–178
- Wang, Z.-M., see Zhu, Z.-L. (4) 171–178
- Yan, B.-Y., see Zhu, Z.-L. (4) 171–178

- Yang, Y.-H., see Zhu, Z.-L. (4) 171–178
- Yasar, A., K. Gunduz, E. Onur and M. Calkan, Serum homocysteine, vitamin B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo (2) 85–89
- Yigit, S., A. Inanir, N. Karakus, E. Kesici and N. Bozkurt, Common mediterranean fever (*MEFV*) gene mutations associated with ankylosing spondylitis in Turkish population (3) 113–118
- Yilmaz, Y., see Colak, Y. (2) 77–83
- Young, R.M., see Morris, C.P. (4) 163–170
- Zaki, M., see Khojasteh-Fard, M. (6) 289–293
- Zavalhia, L.S., M. Romitti, G.C. Netto, G.T. dos Santos, R.T. Meurer, A. Hilbig, M.B. Michalowski and M. de Castro Ribeiro, Evaluation of the expression of C-kit (CD117) in ependymomas and oligodendrogiomas (2) 61–68
- Zemheri, E., see Colak, Y. (2) 77–83
- Zhang, H.-Z., see Zhu, Z.-L. (4) 171–178
- Zhang, X.-H., see Zhu, Z.-L. (4) 171–178
- Zhang, Y., see Zhu, Z.-L. (4) 171–178
- Zhu, Z.-L., B.-Y. Yan, Y. Zhang, Y.-H. Yang, Z.-M. Wang, H.-Z. Zhang, M.-W. Wang, X.-H. Zhang and X.-F. Sun, PINCH expression and its clinicopathological significance in gastric adenocarcinoma (4) 171–178
- Zlámal, F., see Vašků, A. (1) 43–49
- Zunino, G., see Provenzano, G. (5) 225–239